If one tells the truth, one is sure, sooner or later to be found out Oscar Wilde
We recently suggested that inosine 3′,5′-cyclic monophosphate (cIMP) synthesized by soluble guanylyl cyclase (sGC) is the mediator of hypoxic augmentation of coronary vasoconstriction. Here, we explain why we actually believe that cIMP may be considered as a new second messenger.
Cyclic guanosine 3′,5′-monophosphate (cGMP) has long been viewed as the only signaling molecule synthesized by soluble guanylyl cyclase (sGC) (Friebe and Koesling 2009; Waldman and Murad 1987) . However, in addition to cGMP, purified sGC can synthesize several other cyclic nucleotides including inosine 3′,5′-cyclic monophosphate (cIMP) (Beste et al. 2012) . The latter study, by Seifert and his colleagues, came as an illumination to us as we were trying over the years to explain why in isolated arteries hypoxia augments contractions in a counter-intuitive manner that requires the presence of the endothelium, the production of nitric oxide (NO), and the subsequent activation of sGC, but not the presence of cGMP (De Mey and Vanhoutte 1983; Rubanyi and Vanhoutte 1985; Graeser and Vanhoutte 1991; Pearson et al. 1996; Chan et al. 2011) . Hence, in a recent study, we tested and, we believe, proved right, the hypothesis that cIMP may act as a mediator in hypoxic augmentation of coronary vasoconstriction (Chen et al. 2014) . In his editorial commentary, Roland Seifert (Seifert 2014) expressed his skepticism about such a second messenger role for cIMP based on two major arguments: cIMP levels are far below detection limit, and the absence of known target protein for cIMP (Seifert 2014) . We believe that this skepticism largely arises from overlooking our findings in isolated porcine coronary arteries that cIMP levels are markedly elevated by hypoxia and that cIMP at rather low concentrations activates Rho kinase (ROCK), which subsequently promotes hypoxic vasoconstriction (Chen et al. 2014) .
The evidence reiterated by Seifert to support his view that cIMP is far below detection level was obtained in cultured HEK293 cells overexpressing the isoform A of particulate guanylyl cyclases (pGC-A) (Beste et al. 2013) . In a separate study on nucleotidyl cyclase activity in HEK293 cells overexpressing sGC and in RFL-6 rat fibroblasts endogenously expressing sGC, no measurement on cIMP is mentioned (Bähre et al. 2014) . Our experiments were performed ex vivo on relatively intact porcine coronary arteries. In such "fresh" tissues, cIMP was detected using high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS). The level of cIMP was elevated by NO in arteries without endothelium, as well as by inosine 5′-triphosphate (ITP, the substrate for cIMP formation) or by hypoxia in arteries with endothelium. These effects were prevented by ODQ, a selective inhibitor of sGC. The level of cIMP increased also in arteries without endothelium when exposed to hypoxia in the presence of Bay 58-2667, a NO-independent and heme-independent activator of sGC (Follmann et al. 2013 ). Taken in conjunction, these results prompted the unavoidable interpretation that the increased levels of cIMP are produced by sGC (Chen et al. 2014) . The most novel finding of our study is that the sGC-dependent formation of cIMP in the arteries is stimulated by hypoxia. We believe that these findings are solid and will withstand the test of time, as has the NO-and the sGC-dependency of the hypoxic augmentation (Graeser and Vanhoutte 1991; Pearson et al. 1996; Chan et al. 2011; Chen et al. 2014) .
However, we still do not know how and why hypoxia causes sGC to switch substrate. An increased availability of ITP may in part be involved, as supported by the increased ITP level under hypoxia (Chen et al. 2014) . ITP is primarily derived from ATP deamination (Behmanesh et al. 2009; Sakumi, et al. 2010) . An increased intracellular level of cIMP occurs in response to exogenous application of ATP (Ferguson and Price 1973) . ATP is the most abundant nucleotide inside the cell (Gribble et al. 2000) . It has been estimated that 10-25 % of the ATP pool can be converted to ITP by deamination (Sakumi, et al. 2010) . Under normal conditions, ITP is largely degraded by ITPase, and the intracellular level of ITP is rather low (Behmanesh et al. 2009; Sakumi, et al. 2010) . However, if hypoxia were to promote ATP deamination and/or suppress the activity of ITPase, sufficient ITP could accumulate for sGC to synthesize cIMP (Bähre et al. 2014) .
The role of cIMP as a mediator in hypoxic augmentation of vasoconstriction is also questioned by Seifert for the lack of downstream target. As he points out, the affinity of cIMP is rather low for activation of either cGMP-dependent protein kinase (PKG) or cAMP-dependent protein kinase (PKA), classical targets for cyclic nucleotides (Seifert 2014) . We agree that hypoxic augmentation by cIMP is not likely to involve either PKG or PKA as this has been excluded by our previous experiments using various inhibitors of sGC, adenylyl cyclase, PKG, and PKA (Chan et al. 2011) . The hypoxic augmentation of vasoconstriction in arteries with, or in those without endothelium but treated with cIMP, is blunted by the Rho-kinase inhibitor Y27632 (Chan et al. 2011; Chen et al. 2014 ). The phosphorylation of myosin phosphatase target subunit 1 (MYPT1) at Thr853, an indicator of the activation of ROCK (Gao et al. 2007; Somlyo and Somlyo 2003) is stimulated in arteries with endothelium by hypoxia and arteries without endothelium exposed to cIMP. Moreover, in homogenates of coronary arteries, cIMP activates ROCK starting at a concentration of 10 −7 M (Chen et al. 2014) , which is well within the physiological range for the activation of kinases by cyclic nucleotides (Dhanakoti et al. 2000; Wolter et al. 2011) . Activation of ROCK leads to reduced activity of myosin light chain phosphatase (MLCP), consequently increasing the Ca 2+ sensitivity of the myofilaments, and thus augmenting vasoconstriction (Gao et al. 2007; Somlyo and Somlyo 2003) . These findings prompt the suggestion that Rho-kinase is indeed a downstream target for cIMP. However, although the effect of cIMP is prevented by ROCK inhibitors (Chan et al. 2011; Chen et al. 2014) , we still have to determine how ROCK eventually is activated by the cyclic nucleotide. Current knowledge implies that the enzyme can be activated directly only by GTPase-RhoA, arachidonic acid, sphingosine phosphorylcholine, caspase-3, and granzyme B (Duong-Quy et al. 2013) .
In our article, we used "mediator" rather than "second messenger" to describe the role of cIMP in hypoxic augmentation of vasoconstriction (Chen et al. 2014) . It was tempting to indeed propose cIMP as a new second messenger, but we agree with Seifert that this should not be done lightly. To be designated as such, according to Sutherland (Sutherland et al. 1968) , a second messenger molecule should meet the following criteria: (1) its intracellular levels should change in response to a physiologically relevant stimulus; (2) when reaching intracellular compartments, it should mimic the effect of an extracellular stimulus; (3) the effects of the extracellular stimulus should be blocked by antagonism of the action of the messenger; (4) the molecule should be synthesized and metabolized; and (5) specific intracellular binding sites should be present (Aley et al. 2013; Sutherland et al. 1968 ). In our study, the formation of cIMP by sGC was Proposed mechanism for cIMP acting as a mediator in hypoxic augmentation of vasoconstriction. In such, a response hypoxia causes a marked increase in the synthesis of cIMP by soluble guanylyl cyclase (sGC). Cyclic IMP in turn activates rho kinase (ROCK), resulting in reduced activity of myosin light chain phosphatase (MLCP), consequently increased Ca 2+ sensitization of myofilaments and augmented vasoconstriction. Cyclic GMP may counteract the effect of ROCK by stimulating the activity of MLCP via cGMP-depedent protein kinase (PKG). A critical role of cIMP is appreciated by testing the effect of hypoxia on vasoconstriction by (1) activating sGC by endothelium-derived nitric oxide (NO), an exogenous NO donor (DETA NONOate) and Bay 58-2667 (a NO-independent, heme-independent activator of sGC); or by suppressing activation of sGC by inhibition of endothelial NO synthase (eNOS, with nitro-L-arginine), removal of the endothelium and ODQ (selective sGC inhibitor ); and (2) activating ROCK by exogenous cIMP or inhibiting ROCK with Y27632. Full arrows indicate activation. Dotted arrows indicate inhibition stimulated by NO under hypoxic conditions. These changes were associated with the activation of ROCK and hypoxic augmentation of vasoconstriction. The extracellular administration of cIMP also caused a similar phenomenon, presumably following diffusion across the cell membrane (Werner et al. 2011) . Studies using human phosphodiesterases show that cIMP is hydrolyzed (Reinecke et al. 2011 ) and phosphodiesterase inhibition potentiated the hypoxic augmentation (Graeser and Vanhoutte 1991) . Hence, it appears that cIMP meets, or nearly meets all the criteria recommended by Sutherland, except that there is currently no agent available to specifically block the synthesis of cIMP (without affecting that of cGMP).
Soluble guanylyl cyclase is a critical enzyme involved in various functional responses to NO (Friebe and Koesling 2009; Waldman and Murad 1987) . Currently, cGMP is considered to be the only molecule responsible for all the actions resulting from the activation of sGC. However, the available evidence indicates that hypoxia has no significant effect on cGMP formation (Chan et al. 2011; Chen et al. 2014) .Taken in conjunction (Fig. 1) , our ex vivo findings over the years strongly suggest that, at least in isolated porcine coronary arteries, this enzyme can generate another signaling molecule, cIMP, which promotes vasoconstriction under hypoxic conditions, in sharp contrast to the vasodilator role of cGMP (Graeser and Vanhoutte 1991; Pearson et al. 1996; Chan et al. 2011; Chen et al. 2014 ). Tissues do not lie, but one has to understand their language.
